AI offers significant future opportunities in prostate cancer care by enhancing diagnostic accuracy and consistency in imaging interpretation, such as mpMRI and PSMA-PET/CT, and supporting risk stratification and personalized treatment recommendations. This evidence concerns the gene FOLH1 and Familial prostate cancer.